Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 21

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 21
---
-3 (File No. 333-268873).

<div align='center'>4</div>

Merger Transaction

In the second quarter of fiscal
2025, the Company determined that it would be in its and its shareholders best interest to merge with DiamiR On June 2, 2025, we entered
into the Letter of Intent with DiamiR for the acquisition of 100% of the outstanding shares of DiamiR for consideration in shares.

Pursuant to the Letter of
Intent, we entered into the Merger Agreement on July 14, 2025, where the Company will acquire 100% of DiamiR outstanding shares of common
stock with consideration to be paid in shares at the closing (the “DiamiR Closing”). Upon consummation of DiamiR Merger, DiamiR
will become a wholly-owned subsidiary of the Company, and the existing DiamiR stockholders and existing Company shareholders will own
approximately 70% and 30%, respectively, of the outstanding shares of the combined company. Pursuant to the Letter of Intent, the Company
entered into a licensing agreement and management agreement with DiamiR concurrently with the Merger Agreement. The closing of the DiamiR
Merger will be subject to customary closing conditions, including the preparation and receipt of certain audited financials and obtaining
shareholder approval of the DiamiR Merger. Therefore, there is no guarantee that such a transaction will occur.

DiamiR is a molecular diagnostic
company focused on developing minimally invasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer’s,
Parkinson’s, other neurodegenerative diseases, and cancer. The proprietary technology developed at DiamiR is based on quantitative
analysis of circulating organ-enriched microRNAs in plasma. Long term objectives of DiamiR include the development and commercialization
of Lab-Developed tests (LDTs) from its CLIA certified lab based on the identified miRNA expression signatures. In parallel, DiamiR is
also expanding its menu to offer Pharma testing services to companies involved in developing therapeutic and treatment products. These
Pharma services biomarker tests could be used for screening and patient stratification, or as disease and treatment monitoring, or to
better select and characterize patients in clinical trials.

DiamiR was incorporated in
Delaware on June 16, 2014, and primarily operates through its wholly-owned subsidiary, DiamiR, LLC, which